Activating mutations in BRAF (V600) occur in approximately 40% of all melanoma patients and have led to the development of molecular targeted therapies directed against BRAF and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK), two kinases in the mitogen-activated protein kinase pathway (MAPK) [39]. Here, BRAF is linked to melanoma.